Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

121. Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]) (Abstract)

Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]) The mortality rate of most patients with atrial fibrillation (AF) exceeds the stroke rate, but predictors of mortality have not been well defined. The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A) recruited patients with AF who were unsuitable to receive vitamin K

2018 EvidenceUpdates

122. [Trancatheter ablation with cryoballoon for the treatment of atrial fibrillation. A rapid assessment]

[Trancatheter ablation with cryoballoon for the treatment of atrial fibrillation. A rapid assessment] Ablazione transcatetere mediante criopallone per il trattamento della fibrillazione atriale. Valutazione rapida [Trancatheter ablation with cryoballoon for the treatment of atrial fibrillation. A rapid assessment] Ablazione transcatetere mediante criopallone per il trattamento della fibrillazione atriale. Valutazione rapida [Trancatheter ablation with cryoballoon for the treatment of atrial (...) fibrillation. A rapid assessment] Negro A, Maltoni S, Pecoraro V, Camerlingo M, Falasca G, Lauretti F. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Negro A, Maltoni S, Pecoraro V, Camerlingo M, Falasca G, Lauretti F.. Ablazione transcatetere mediante criopallone per il trattamento della fibrillazione atriale. Valutazione rapida. [Trancatheter

2018 Health Technology Assessment (HTA) Database.

123. Catheter Ablation for Atrial Fibrillation with Heart Failure. Full Text available with Trip Pro

Catheter Ablation for Atrial Fibrillation with Heart Failure. Mortality and morbidity are higher among patients with atrial fibrillation and heart failure than among those with heart failure alone. Catheter ablation for atrial fibrillation has been proposed as a means of improving outcomes among patients with heart failure who are otherwise receiving appropriate treatment.We randomly assigned patients with symptomatic paroxysmal or persistent atrial fibrillation who did not have a response (...) to antiarrhythmic drugs, had unacceptable side effects, or were unwilling to take these drugs to undergo either catheter ablation (179 patients) or medical therapy (rate or rhythm control) (184 patients) for atrial fibrillation in addition to guidelines-based therapy for heart failure. All the patients had New York Heart Association class II, III, or IV heart failure, a left ventricular ejection fraction of 35% or less, and an implanted defibrillator. The primary end point was a composite of death from any

2018 NEJM Controlled trial quality: predicted high

124. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation Full Text available with Trip Pro

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation Randomized clinical trials comparing direct oral anticoagulants (DOACs) to warfarin in cancer patients have not been performed. We evaluated the effectiveness and associated risk of DOACs vs warfarin, as well as comparisons of DOACs, in a large population of cancer patients with nonvalvular atrial fibrillation (AF). Using the MarketScan databases, we identified 16 096 AF patients

2018 Blood advances

125. Evaluation of asymptomatic atrial fibrillation

Evaluation of asymptomatic atrial fibrillation Evaluation of asymptomatic atrial fibrillation Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Evaluation of asymptomatic atrial fibrillation View/ Open Date 2012-09 Format Metadata Abstract In hemodynamically stable patients without acute chest pain, the evaluation (...) and treatment of atrial fibrillation should not change based on symptoms alone. (Strength of Recommendation: A, based on multiple cohort studies.) As many as 75 percent of episodes of atrial fibrillation are not recognized by patients, and it is not uncommon for asymptomatic episodes to last more than 48 hours, which increases the risk of thromboembolic complications. URI Citation American Family Physician, 86(6) 2012. Collections hosted by hosted by

2018 Clinical Inquiries

126. Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. Full Text available with Trip Pro

Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. The left atrial appendage is a key site of thrombus formation in atrial fibrillation (AF) and can be occluded or removed at the time of cardiac surgery. There is limited evidence regarding the effectiveness of surgical left atrial appendage occlusion (S-LAAO) for reducing the risk of thromboembolism.To evaluate the association

2018 JAMA

127. Evaluation of the Incidence of New-Onset Atrial Fibrillation After Aortic Valve Replacement (Abstract)

Evaluation of the Incidence of New-Onset Atrial Fibrillation After Aortic Valve Replacement Data on the burden of new-onset atrial fibrillation after transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (AVR) is limited mostly to small series or post hoc analyses of clinical trials.To evaluate the incidence of new-onset atrial fibrillation and assess the incidence of in-hospital mortality associated with new-onset atrial fibrillation after TAVI and AVR.In (...) this population-based observational study using the National Inpatient Sample and a validation cohort from the New York state inpatient database, the National Inpatient Sample was queried from January 1, 2012, to September 30, 2015, and the New York state inpatient database was queried from January 1, 2012, to December 31, 2014. Hospitalizations of adults undergoing TAVI or isolated AVR were examined. The incidence of in-hospital mortality across groups with new-onset atrial fibrillation was assessed

2018 EvidenceUpdates

128. Atrial Fibrillation Full Text available with Trip Pro

Atrial Fibrillation National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018 - Heart, Lung and Circulation Follow Email/Username: Password: Remember me Search Terms Search within Search Access provided by Volume 27, Issue 10, Pages 1209–1266 National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines (...) for the Diagnosis and Management of Atrial Fibrillation 2018 NHFA CSANZ Atrial Fibrillation Guideline Working Group 1 , x David Brieger Affiliations Department of Cardiology, Concord Hospital, Sydney , Australia University of Sydney, Sydney , Australia Correspondence Corresponding author. , MBBS, PhD, FCSANZ a , b , , x David Brieger Affiliations Department of Cardiology, Concord Hospital, Sydney , Australia University of Sydney, Sydney , Australia Correspondence Corresponding author. , x John Amerena

2018 Cardiac Society of Australia and New Zealand

129. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 Full Text available with Trip Pro

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date (...) range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 David Brieger, John Amerena, John R Attia, Beata Bajorek, Kim H Chan

2018 MJA Clinical Guidelines

130. Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review

Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review | CADTH.ca Find the information you need Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart (...) Failure: A Rapid Qualitative Review Last updated: September 17, 2018 Project Number: RC1019-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question How do patients experience, make decisions around, and live with outpatient cardiac monitors for the diagnosis of stroke, atrial fibrillation, and/or heart failure? Key Message The onset of cardiac monitor use accompanies many life changes and new personal responsibilities. For some

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

131. Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF. (Abstract)

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF. The management of anticoagulation therapy in patients with atrial fibrillation (AF) and cancer is challenging due to increased thrombotic and bleeding risks. We sought to determine the safety and efficacy of rivaroxaban in patients with AF and a history of cancer.ROCKET AF randomized 14,264 patients with AF to rivaroxaban or warfarin

2018 European heart journal. Quality of care & clinical outcomes Controlled trial quality: predicted high

132. New-onset atrial fibrillation

New-onset atrial fibrillation New-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  New-onset atrial fibrillation Last reviewed: February 2019 Last updated: June 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age and affects almost 5% of the population older than 69 years of age. Causes significant morbidity and mortality including (...) palpitations, dyspnoea, angina, dizziness or syncope, and features of congestive heart failure (CHF), tachycardia-induced cardiomyopathy, stroke, and death. ECG shows absent P waves, presence of fibrillatory waves, and irregularly irregular QRS complexes. Most patients presenting with new-onset or 'acute' atrial fibrillation (AF) do not require immediate cardioversion. Most patients will require medical therapy to control ventricular rate. Patients who develop haemodynamic compromise should have immediate

2018 BMJ Best Practice

133. Chronic atrial fibrillation

Chronic atrial fibrillation Chronic atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic atrial fibrillation Last reviewed: February 2019 Last updated: October 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age. Patients frequently have co-existing cardiac or non-cardiac conditions, such as hypertension, coronary artery disease (...) , pacemakers, and ablation of the atrioventricular node need to be weighed based on multiple clinical factors to optimise patient outcome. Definition Atrial fibrillation (AF) is a supraventricular tachyarrhythmia. It is characterised by uncoordinated atrial activity on the surface ECG, with fibrillatory waves of varying shapes, amplitudes, and timing associated with an irregularly irregular ventricular response when atrioventricular (AV) conduction is intact. [Figure caption and citation for the preceding

2018 BMJ Best Practice

134. Less dementia with oral anticoagulation in atrial fibrillation Full Text available with Trip Pro

Less dementia with oral anticoagulation in atrial fibrillation The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.Retrospective registry study of all patients

2018 EvidenceUpdates

135. Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults)

Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) NHS England » Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) Search Search Menu Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative (...) or absolute contraindications to anticoagulation (adults) Document first published: 9 July 2018 Page updated: 9 July 2018 Topic: , Publication type: This policy document outlines the arrangements for funding of treatment for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation. Document PDF 572 KB 28 pages

2018 NHS England

136. NOACs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation

NOACs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation '); } else { document.write(' '); } ACE | Novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation Search > > Novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation - Novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial (...) fibrillation First published on 3 May 2017 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and : CHA 2 DS 2 -VASc score of 1 or more for men; and CHA 2 DS 2 -VASc score of 2 or more for women. Rivaroxaban or apixaban should not be used in patients with valvular AF (especially rheumatic mitral

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

137. Atrial Fibrillation: Screening With Electrocardiography

Atrial Fibrillation: Screening With Electrocardiography Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for atrial fibrillation with electrocardiography (ECG). See the Clinical Considerations section (...) for suggestions for practice regarding the I statement. I View the Clinical Summary in Population Older adults Recommendation No recommendation. Grade: I (insufficient evidence) Risk Assessment Atrial fibrillation is strongly associated with older age and obesity. Other risk factors include high blood pressure, diabetes, heart failure, prior cardiothoracic surgery, current smoking, prior stroke, sleep apnea, alcohol and drug use, and hyperthyroidism. Screening Tests The USPSTF found inadequate evidence

2018 U.S. Preventive Services Task Force

138. Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study Full Text available with Trip Pro

Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study Atrial fibrillation (AF) is associated with a high risk of thromboembolic stroke and oral anticoagulation therapy (OAT) is able to reduce the rate of ischemic events. Nevertheless, the actual benefit of prolonged OAT after successful radiofrequency catheter ablation (RFCA) is not clear yet.Scientific investigations were assumed suitable if they assessed

2017 Frontiers in cardiovascular medicine

139. Ablation of Atrial Fibrillation in Patients with Congenital Heart Disease Full Text available with Trip Pro

Ablation of Atrial Fibrillation in Patients with Congenital Heart Disease With improved surgical techniques and medical management for patients with congenital heart diseases, more patients are living longer and well into adulthood. This improved survival comes with a price of increased morbidity, mainly secondary to increased risk of tachyarrhythmias. One of the major arrhythmias commonly encountered in this subset of cardiac patients is AF. Similar to the general population, the risk of AF (...) . This review will shed light on the procedural techniques, success rates and complications of AF catheter ablation in patients with different types of CHD, including atrial septal defects, tetralogy of Fallot, persistent left superior vena cava, heterotaxy syndrome and atrial isomerism, and Ebstein anomaly.

2017 Arrhythmia & electrophysiology review

140. Ablation of Atrial Fibrillation Drivers Full Text available with Trip Pro

Ablation of Atrial Fibrillation Drivers Pulmonary vein isolation (PVI) is central to ablation approaches for atrial fibrillation (AF), yet many patients still have arrhythmia recurrence after one or more procedures, despite evolving technologies for PVI. Ablation of localised AF drivers, which lie outside the pulmonary veins in many patients, is a practical approach that has been shown to improve success by many groups. Such localised drivers lie in atrial regions shown mechanistically

2017 Arrhythmia & electrophysiology review